glp-1 drugs and fatty liver Why are agonists being used to treat patients with nonalcoholic disease? Glucagon-like peptide-1 and glucagon-like peptide-2

Glycaemic control typically improves within the first few weeks, whilst significant weight loss and associated energy improvements may take 3-6 months to become apparent

and are illegal

Glucagon-like Peptide 1-related Peptides Increase Nitric Oxide Effects to Reduce Platelet Activation

Only Wegovy (semaglutide) is FDA-approved specifically for weight management in people without diabetes

Insurance companies have become more strict when it comes to covering the drugs, rejecting claims even for patients with diabetes already on the drug

One of this years Life Sciences prizes was jointly awarded to five scientists for the discovery and characterization of glucagon-like peptide 1 (GLP-1), revealing its potential in treating diabetes and obesity